Arthur Higgins - Zimmer Biomet Independent Director
| ZBH Stock | USD 110.96 0.74 0.67% |
Director
Mr. Arthur J. Higgins is Independent Director of Zimmer Biomet Holdings, Inc. He is President, Chief Executive Officer and a member of the board of directors of Depomed, Inc. since March 2017. Consultant, Blackstone Healthcare Partners of The Blackstone Group since June 2010. Previously, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry. Arthur J. Higgins has extensive senior leadership experience in the global healthcare market. Through leadership positions with large healthcare developers and manufacturers in both the U.S. and Europe, he has gained deep knowledge of the healthcare market and the strategies for developing and marketing products in this highly regulated area. His knowledge and industry background allow him to provide valuable insight to our business. since 2007.
| Age | 65 |
| Tenure | 17 years |
| Address | 345 East Main Street, Warsaw, IN, United States, 46580 |
| Phone | 574 373 3333 |
| Web | https://www.zimmerbiomet.com |
Arthur Higgins Latest Insider Activity
Tracking and analyzing the buying and selling activities of Arthur Higgins against Zimmer Biomet stock is an integral part of due diligence when investing in Zimmer Biomet. Arthur Higgins insider activity provides valuable insight into whether Zimmer Biomet is net buyers or sellers over its current business cycle. Note, Zimmer Biomet insiders must abide by specific rules, including filing SEC forms every time they buy or sell Zimmer Biomet'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Arthur Higgins over six months ago Acquisition by Arthur Higgins of 1068 shares of Zimmer Biomet subject to Rule 16b-3 |
Zimmer Biomet Management Efficiency
The company has Return on Asset of 0.0461 % which means that on every $100 spent on assets, it made $0.0461 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0871 %, implying that it generated $0.0871 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The Zimmer Biomet's current Return On Tangible Assets is estimated to increase to 0.18, while Return On Capital Employed is projected to decrease to 0.07. As of now, Zimmer Biomet's Fixed Asset Turnover is decreasing as compared to previous years. The Zimmer Biomet's current Asset Turnover is estimated to increase to 0.68, while Total Assets are projected to decrease to under 13.7 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James Lenehan | Medtronic PLC | 71 | |
| Leslie Heisz | Edwards Lifesciences Corp | 60 | |
| Phebe Novakovic | Abbott Laboratories | 62 | |
| Srikant Datar | Stryker | 68 | |
| Donna James | Boston Scientific Corp | 63 | |
| Mark Foley | Glaukos Corp | 55 | |
| Richard Anderson | Medtronic PLC | 65 | |
| Jerome Lande | CONMED | 45 | |
| David Wichmann | Boston Scientific Corp | 58 | |
| David Hoffmeister | Glaukos Corp | 66 | |
| Denise OLeary | Medtronic PLC | 62 | |
| Alvin Jeffers | Integer Holdings Corp | 47 | |
| Scott Donnelly | Medtronic PLC | 59 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Sally Blount | Abbott Laboratories | 59 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Patricia Gonzalez | Abbott Laboratories | 49 | |
| Michelle Kumbier | Abbott Laboratories | 53 | |
| Glenn Tilton | Abbott Laboratories | 72 | |
| Joel Suiter | SurModics | N/A | |
| Elizabeth Nabel | Medtronic PLC | 69 | |
Management Performance
| Return On Equity | 0.0871 | ||||
| Return On Asset | 0.0461 |
Zimmer Biomet Holdings Leadership Team
Elected by the shareholders, the Zimmer Biomet's board of directors comprises two types of representatives: Zimmer Biomet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zimmer. The board's role is to monitor Zimmer Biomet's management team and ensure that shareholders' interests are well served. Zimmer Biomet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zimmer Biomet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sreelakshmi Kolli, Independent Director | ||
| Didier Deltort, President - Europe, Middle East and Africa | ||
| Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
| Arthur Higgins, Independent Director | ||
| Michael Michelson, Independent Director | ||
| Larry Glasscock, Independent Non-Executive Chairman of the Board | ||
| Nitin Goyal, Chief Science, Technology and Innovation Officer | ||
| Ellison Humphrey, Senior Vice President, Chief Transformation Officer | ||
| Chad JD, General VP | ||
| Derek Davis, Chief Accounting Officer, Vice President, Controller | ||
| Ivan Tornos, Group President - Global Businesses and Americas | ||
| Angela Main, Global VP | ||
| Wilfred Zuilen, President - Europe, Middle East and Africa | ||
| Suketu Upadhyay, Chief Financial Officer, Executive Vice President | ||
| Zeeshan Tariq, Senior Officer | ||
| Christopher Begley, Lead Independent Director | ||
| Bryan Hanson, Chairman of the Board, President, Chief Executive Officer | ||
| Sang Yi, President Asia Pacific | ||
| Betsy Bernard, Independent Director | ||
| Keri Mattox, Senior Vice President - Investor Relations, Chief Communications Officer | ||
| Maria Hilado, Independent Director | ||
| Rachel Ellingson, Senior Vice President Chief Strategy Officer, Executive Officer | ||
| Nitin MD, Technology Science | ||
| Chad Phipps, Senior Vice President, General Counsel, Secretary | ||
| Syed Jafry, Independent Director | ||
| Paul Stellato, Controller VP | ||
| Michael Farrell, Independent Director | ||
| Lori Winkler, Chief Human Resource Officer, Senior Vice President | ||
| Zachary CPA, Director Relations | ||
| David DeMartino, Senior Relations | ||
| Gail Boudreaux, Independent Director | ||
| Shaun Braun, Senior Officer | ||
| Robert Hagemann, Independent Director |
Zimmer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zimmer Biomet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0871 | ||||
| Return On Asset | 0.0461 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 27.95 B | ||||
| Shares Outstanding | 199.07 M | ||||
| Shares Owned By Insiders | 0.14 % | ||||
| Shares Owned By Institutions | 93.43 % | ||||
| Number Of Shares Shorted | 6.69 M | ||||
| Price To Earning | 77.41 X |
Currently Active Assets on Macroaxis
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.597 | Dividend Share 0.96 | Earnings Share 5.24 | Revenue Per Share 37.006 | Quarterly Revenue Growth 0.04 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.